应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09966 康宁杰瑞制药-B
已收盘 07-29 16:08:21
7.560
-0.380
-4.79%
最高
7.940
最低
7.440
成交量
89.70万
今开
7.940
昨收
7.940
日振幅
6.30%
总市值
73.26亿
流通市值
73.26亿
总股本
9.69亿
成交额
683.06万
换手率
0.09%
流通股本
9.69亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大
金吾财讯 · 07-28 10:01
【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大
创新药连续大涨，这次真的不一样了吗？
华尔街见闻 · 07-16
创新药连续大涨，这次真的不一样了吗？
港股异动 | 康宁杰瑞制药-B(09966)涨超10% KN026再获突破性疗法认定，用于一线HER2阳性乳腺癌
智通财经 · 07-15
港股异动 | 康宁杰瑞制药-B(09966)涨超10% KN026再获突破性疗法认定，用于一线HER2阳性乳腺癌
康宁杰瑞制药-B：安尼妥单抗联合HB1801一线治疗HER2+晚期乳腺癌再获国家药监局突破性疗法认定
公告速递 · 07-14
康宁杰瑞制药-B：安尼妥单抗联合HB1801一线治疗HER2+晚期乳腺癌再获国家药监局突破性疗法认定
恒生科技指数跌幅扩大至2% 智谱、百度跌超7%
新浪港股 · 07-14
恒生科技指数跌幅扩大至2% 智谱、百度跌超7%
康宁杰瑞制药-B更新2026年6月股份变动月报表，股本维持稳定
公告速递 · 07-07
康宁杰瑞制药-B更新2026年6月股份变动月报表，股本维持稳定
【券商聚焦】国海证券首予康宁杰瑞制药(09966)增持评级 指核心产品获批开启商业化
金吾财讯 · 07-06
【券商聚焦】国海证券首予康宁杰瑞制药(09966)增持评级 指核心产品获批开启商业化
港股直击 | 生物医药股及医药外包股造好，康宁杰瑞制药、康诺亚升7%，荣昌生物、昭衍新药升5%
老虎资讯综合 · 06-23
港股直击 | 生物医药股及医药外包股造好，康宁杰瑞制药、康诺亚升7%，荣昌生物、昭衍新药升5%
【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大
金吾财讯 · 06-15
【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大
智通港股早知道 | 美国5月CPI同比上涨4.2% 工信部：加强高端光电芯片和器件研发
智通财经 · 06-11
智通港股早知道 | 美国5月CPI同比上涨4.2% 工信部：加强高端光电芯片和器件研发
康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)一线治疗HER2阳性晚期乳腺癌的III期临床研究达到主要终点
智通财经 · 06-10
康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)一线治疗HER2阳性晚期乳腺癌的III期临床研究达到主要终点
康宁杰瑞制药-B：安博利单抗（KN026）一线治疗HER2+晚期乳腺癌III期临床研究达到主要终点
美股速递 · 06-10
康宁杰瑞制药-B：安博利单抗（KN026）一线治疗HER2+晚期乳腺癌III期临床研究达到主要终点
康宁杰瑞制药-B：执行董事及管理层增持股份
新浪港股 · 06-05
康宁杰瑞制药-B：执行董事及管理层增持股份
康宁杰瑞制药-B6月4日回购15.60万股股份，总额约110.85万港元
公告速递 · 06-05
康宁杰瑞制药-B6月4日回购15.60万股股份，总额约110.85万港元
康宁杰瑞制药-B(09966)6月4日斥资110.85万港元回购15.6万股
智通财经 · 06-05
康宁杰瑞制药-B(09966)6月4日斥资110.85万港元回购15.6万股
康宁杰瑞制药-B：股份回购总代价达499万港元，每股作价7.375港元
美股速递 · 06-05
康宁杰瑞制药-B：股份回购总代价达499万港元，每股作价7.375港元
康宁杰瑞制药-B2026年5月股份变动月报：新增发行88,000股
公告速递 · 06-04
康宁杰瑞制药-B2026年5月股份变动月报：新增发行88,000股
康宁杰瑞制药-B(09966)：JSKN016的最新研究成果于2026年ASCO年会呈列
中金财经 · 06-02
康宁杰瑞制药-B(09966)：JSKN016的最新研究成果于2026年ASCO年会呈列
康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗BC的III期临床研究结果于2026 ASCO年会以LBA口头报告形式呈列
智通财经 · 06-01
康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗BC的III期临床研究结果于2026 ASCO年会以LBA口头报告形式呈列
智通港股早知道 | 2026年国家医保目录调整工作方案发布 汇量科技(01860)Q1收入同比增长32.2%
智通财经 · 06-01
智通港股早知道 | 2026年国家医保目录调整工作方案发布 汇量科技(01860)Q1收入同比增长32.2%
加载更多
公司概况
公司名称：
康宁杰瑞制药-B
所属市场：
SEHK
上市日期：
--
主营业务：
康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的ADCs、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的候选药物包括KN046（PD-L1/CTLA-4双特异性抗体）, KN026（抗HER2双特异性抗体）, KN035（皮下注射PD-L1）, JSKN003（HER2双表位ADC）等，用于1L sq NSCLC、乳腺癌 2+HER L1、晚期实体瘤、HER2表达实体瘤等适应症。
发行价格：
--
{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":7.56,"timestamp":1785312501004,"preClose":7.94,"halted":0,"volume":897000,"delay":0,"changeRate":-0.04785894206549128,"floatShares":969000000,"shares":969000000,"eps":-0.13902028139852238,"marketStatus":"已收盘","change":-0.38,"latestTime":"07-29 16:08:21","open":7.94,"high":7.94,"low":7.44,"amount":6830632,"amplitude":0.062972,"askPrice":7.6,"askSize":22000,"bidPrice":7.55,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.13902028139852238,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785375000000},"marketStatusCode":5,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":7.94,"openAndCloseTimeList":[[1785288600000,1785297600000],[1785301200000,1785312000000]],"volumeRatio":0.867169,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966","defaultTab":"news","newsList":[{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","06996","LU0856984785.SGD","06990","03329","09926","LU0572944931.SGD","02096","02269","01801","LU2476274308.USD","LU2399975544.HKD","LU1880383366.USD","01177","03692","09996","LU1813983027.USD","159938","01951","01548","LU2097828714.EUR","02162","09939","KCE","02273","HK0000320223.HKD","BK1219","LU2328871848.SGD","BK1587","LU0417516571.SGD","09966","01530","00013","06160","KURE","LU0634319403.HKD","LU2039709279.SGD","03759","01093","BK1521","LU0588546209.SGD","06078","HK0000165453.HKD","LU0196878994.USD","LU0348783233.USD","LU1720050803.USD","02268","02596","01952","06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","159992","MEDX","09688","02268","03759","BK1161","09606","02137","03347","09966","02269","06978","BK1574","IBBQ","01672","00241","06606","09995","06996","02359","06618","01801"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651843514","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超10% KN026再获突破性疗法认定，用于一线HER2阳性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2651843514","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651843514?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:35","pubTimestamp":1784082942,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超10%，截至发稿，涨10.43%，报8.15港元，成交额597.46万港元。这是恩尼妥继HER2阳性胃癌后获得的第二项突破性疗法认定。据悉，2026年5月，恩尼妥已正式获批胃癌适应症上市，成为国内自主研发的首个商业化HER2双特异性抗体，标志着本土创新在双抗领域的重要突破。公司表示，此次突破性疗法认定，将加速恩尼妥晚期乳腺癌适应症的研发进程及审评审批进度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","VXUS","BK4585","BK1161","09966","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113965191","title":"康宁杰瑞制药-B：安尼妥单抗联合HB1801一线治疗HER2+晚期乳腺癌再获国家药监局突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1113965191","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113965191?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:05","pubTimestamp":1784027140,"startTime":"0","endTime":"0","summary":"2026年7月14日，康宁杰瑞制药-B（09966.HK）发布自愿公告称，公司与石药集团有限公司（股份代号：1093）附属公司上海津曼特生物科技有限公司共同开发的安尼妥单抗（商品名：恩尼妥®，研发代号：KN026）联合注射用多西他赛（白蛋白结合型）（HB1801），用于一线治疗不可切除或转移性人类表皮生长因子受体2阳性（HER2+）成人乳腺癌，获得国家药品监督管理局药品审评中心（CDE）授予的突破性疗法认定（BTD）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651123013","title":"恒生科技指数跌幅扩大至2% 智谱、百度跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651123013","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651123013?lang=zh_cn&edition=full","pubTime":"2026-07-14 09:52","pubTimestamp":1783993920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 7月14日消息，科指盘初跌幅扩大至2%，恒指跌超1%。科指成分股中，智谱、百度跌超7%，商汤跌超6%，MINIMAX跌近5%，阿里巴巴跌近3%。\n 高盛最新中国策略维持“A股优于H股、硬科技优于软科技”的战术偏好，但开始关注H股大型互联网在估值下调后的修复机会。H股持续反弹的关键不在估值，而在盈利：互联网补贴损失、AI资本开支仍压制利润。中国AI不被整体视作泡沫，但半导体和部分A股硬科技已出现局部过热迹象。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-07-14/doc-inihtrnc7383112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0675040207.SGD","BK1587","LU0541501648.USD","LU3063872942.SGD","LU2125910849.SGD","IE0008368304.USD","LU0979878070.USD","LU1880383440.USD","LU1328277881.USD","BK1588","LU0823038988.USD","LU0488056044.USD","IE00B5MMRT66.SGD","FDNI","LU0196878994.USD","LU1868838027.USD","BK1109","LU0329678337.USD","LU1981816686.USD","LU0197773673.USD","LU0054450605.USD","LU0608807433.USD","LU0329678170.USD","LU0345776255.USD","LU2294711473.HKD","LU0210527791.USD","LU1211504680.USD","LU1810669033.SGD","09888","LU1880383366.USD","LU0117841782.USD","LU0588546209.SGD","LU2097829019.USD","SG9999006514.SGD","09988","LU0531970944.HKD","LU0651946864.USD","LU0672654166.SGD","LU0164865239.USD","LU1224444064.USD","LU0762541174.USD","HK0000286598.CNH","LU1316542783.SGD","BK1575","LU0054237671.USD","03088","LU0370786039.SGD","LU2476274308.USD","LU0417516571.SGD","LU1769817096.USD","LU2357305700.SGD","LU2488822045.USD","LU0642271901.SGD","BKF","SG9999001903.USD","LU0417516902.SGD","LU0048388663.USD","LU0856984785.SGD","07552","LU0287142896.SGD","LU1515016050.SGD","LU1303224171.USD","BK1591","LU0823041008.USD","LU0823426480.USD","SGXZ90724238.SGD","LU2449936058.SGD","LU1769817179.HKD","LU0784639295.USD","LU0106252389.USD","LU1720051108.HKD","BK1618","IE00BMPRXN33.USD","LU0890818403.SGD","BK1613","LU0516423174.USD","LU0417516738.SGD","LU0871576103.HKD","LU1439103000.SGD","HK0000107257.USD","BIDU","LU0737861772.HKD","LU0396098781.USD","LU0143863784.USD","LU0261950983.USD","HK0000320264.USD","LU2125910500.SGD","LU0061477393.USD","LU0737861699.HKD","LU0577902611.USD","LU1808992512.USD","IE0032431581.USD","LU0648948544.HKD","LU0499858602.USD","BK1608","07226","LU0607220059.USD","02837","BK1521","LDEM","LU0039217434.USD","LU0106259558.USD","LU0254981946.USD","LU0594300179.USD","LU0588545730.USD","LU1481107354.HKD","LU0348805143.USD","LU0431992006.USD","SG9999001226.SGD","LU1282649141.HKD","LU0293314216.USD","LU0608807946.USD","LU0244354667.USD","LU0149721374.USD","LU1880398471.USD","LU0823039010.USD","LU0359201885.HKD","LU0043850808.USD","LU0516422440.USD","LU0577902538.SGD","LU0214875030.USD","BK1501","LU1813983027.USD","LU0029875118.USD","LU0831093199.SGD","IE00B0JY6N72.USD","BK1117","SG9999002562.SGD","LU0327786744.USD","LU0791591158.USD","03067","LU0873338254.USD","BK1142","LU0561508036.HKD","LU1794554557.SGD","LU0359202008.SGD","LU1328615791.USD","LU0648000940.SGD","LU2778985437.USD","IE00B0169N27.USD","LU1051769294.HKD","LU1224709979.USD","LU1323998911.USD","CXSE","BK1095","LU0650527681.SGD","LU1201861165.SGD","LU0499858438.USD","LU0326950275.SGD","LU1504937902.USD","LU0831103253.SGD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU0634319403.HKD","LU0823426308.USD","LU0117844026.USD","LU2476274720.SGD","SG9999001093.SGD","LU0348825331.USD","LU0320764243.SGD","LU1960683339.HKD","80020","89988","KWEB","SG9999006597.SGD","LU0823397285.USD","LU0211977185.USD","LU1720051017.SGD","LU0048580855.USD","LU0589944569.HKD","LU0828237940.HKD","LU0630378692.HKD","LU0862451753.SGD","09088","LU0762542818.HKD","LU0531971595.HKD","LU1282649067.USD","LU2097828714.EUR","LU0762540952.USD","SG9999004220.SGD","LU1831875114.USD","LU0348784397.USD","LU0047713382.USD","LU1688375341.USD","LU0516422952.EUR","LU0541502299.USD","LU0594300419.USD","00020","LU1770036033.HKD","LU0251144936.SGD","LU0181495838.USD","LU0320764755.SGD","LU1366334651.USD","LU0084288322.USD","LU2097828805.USD","LU0823397103.USD","LU1282651048.USD","LU0128522744.USD","LU2242644610.SGD","LU2293587155.HKD","LU0307460666.USD","LU1242518931.SGD","LU0886674414.USD","IE00BPRC5H50.USD","ALBmain","LU0231483743.USD","TCHI","LU0164880469.USD","LU0169518387.USD","LU1044876610.USD","LU1720050803.USD","LU0011963245.USD","LU0821914370.USD","LU0348788117.USD","LU0259732245.USD","LU0540923850.HKD","LU1282651121.HKD","LU0543330483.HKD","LU0593848301.USD","LU0130103400.USD","LU0868486357.SGD","LU0865486749.SGD","LU1242518857.USD","LU2257852520.SGD","LU0261947096.USD","BK1574","LU1051768304.USD","LU0128522157.USD","03032","LU1880398554.USD","LU1048588211.SGD","HK0000306701.USD","LU0823413587.USD","IE00BZ08YT58.USD","SG9999002463.SGD","LU0700851271.USD","LU0130518102.USD","LU1188198961.HKD","LU0449515922.USD","LU0143863198.USD","LU0348783233.USD","BK1517","LU0572939691.SGD","LU0210526637.USD","LU0235996351.USD","LU0577902298.EUR","LU2097828474.EUR","LU0543330566.HKD","BK1249","IE00BMPRXR70.SGD","LU0228367735.SGD","LU0173614495.USD","LU1048596156.SGD","LU0127658192.USD","SG9999000459.SGD","LU0140636845.USD","LU0072462343.USD","LU0048597586.USD","BABA","LU0630378429.USD","LU0315179316.USD","LU0455707207.USD","BK1586","LU0819123356.HKD","LU1251922891.USD","LU0149534421.HKD","LU0051755006.USD","LU0469268626.HKD","LU0384037296.USD","LU0611395673.USD","LU0640798160.USD","LU1807302812.USD","SG9999014674.SGD","HSI","03423","09966","LU1282649810.SGD","LU0791590937.USD","LU0577902371.SGD","LU1568876335.HKD","LU1961090484.USD","LU0588545490.SGD","LU0477156797.USD","LU0049853897.USD","LU0348827113.USD","LU1366334578.USD","LU0106959298.USD","SG9999002828.SGD","LU1868837565.USD","LU0359201612.USD","LU0320764599.SGD","LU0165289439.USD","LU0228659784.USD","SG9999001689.USD","LU1956131251.USD","LU0264606111.USD","LU1770034418.SGD","09067","SG9999001051.SGD","02513","LU2097828631.EUR","BK1610","LU0605514214.HKD","LU2045819591.USD","HK0000306685.HKD","LU1548497426.USD","LU0898667661.SGD","LU1655091459.SGD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0456846285.SGD","LU0708995153.HKD","SGXZ86797644.SGD","LU1044875133.USD","LU0348735423.USD","LU0516422366.SGD","LU0052750758.USD","LU0823040885.USD","LU1196710864.SGD","BK1615","03417","LU0572940350.SGD","SGXZ62798434.SGD","HK0000151867.HKD","LU0132412106.USD","LU0502904849.HKD","SG9999000327.SGD","LU0651947912.USD","LU0345775950.USD","LU1048484197.HKD","LU0577902454.USD","LU0823413660.USD","HBBD.SI","LU0163747925.USD","LU2152927971.USD","LU0229945570.USD","LU0096374516.USD","LU1642822792.SGD","LU0029874905.USD","LU1115378108.SGD","LU0862451837.USD","89888","LU0164872284.USD","BK1161","LU0328353924.USD","LU2399975544.HKD","BK1609","LU1719994722.HKD","IE0034224299.USD","LU2087589342.USD","LU0314109678.HKD","LU0588545904.SGD","LU0197773160.USD","03033","LU0348783662.USD","LU1044874839.SGD","IE0003895053.USD","BK1502","LU0315178854.USD","LU0449509016.USD","LU1568876251.USD","LU0572944931.SGD","LU0441854154.USD","LU0516423091.SGD","IE00B543WZ88.USD","IE00B3M56506.USD","LU0463099449.HKD","HSTECH","LU0828237510.HKD","LU0456827905.SGD","BK1584","LU2097828557.USD","HK0000320223.HKD","LU0708995583.HKD","LU0819121731.USD","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155109886","title":"康宁杰瑞制药-B更新2026年6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1155109886","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155109886?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:52","pubTimestamp":1783414376,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年7月7日披露了截至2026年6月30日的股份变动月报表。公告显示，截至本月底，公司法定注册股本维持在25,100,000,000股普通股，每股面值为USD 0.000002，总额USD 50,200，较上月底未发生变动。从已发行股份及库存股份变动情况来看，公司月初已发行股份为968,662,697股，库存股份为5,719,000股；报告期内公司回购股份156,000股，并将其作为库存股份持有。至本月底，已发行股份降至968,506,697股，库存股份增至5,875,000股，总股本仍维持在974,381,697股，与上月持平。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649646742","title":"【券商聚焦】国海证券首予康宁杰瑞制药(09966)增持评级 指核心产品获批开启商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2649646742","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649646742?lang=zh_cn&edition=full","pubTime":"2026-07-06 14:50","pubTimestamp":1783320600,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国海证券发布研报指，康宁杰瑞制药-B 核心产品安尼妥单抗于2026年5月获批上市，用于治疗既往经治的HER2阳性晚期胃或胃食管结合部腺癌，标志着公司开启商业化新纪元。国海证券预测，凭借安尼妥单抗的上市及适应症拓展，其销售额有望在2032年达到峰值26.37亿元人民币。首次覆盖，给予公司“增持”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000750","09966","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131093292","title":"港股直击 | 生物医药股及医药外包股造好，康宁杰瑞制药、康诺亚升7%，荣昌生物、昭衍新药升5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131093292","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131093292?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:49","pubTimestamp":1782179371,"startTime":"0","endTime":"0","summary":"生物医药股及医药外包股造好，康宁杰瑞制药、康诺亚升7%，荣昌生物、昭衍新药升5%，药明巨诺升3%。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","09966","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","LU0456827905.SGD","HK0000306685.HKD","01548","LU0140636845.USD","LU3063872942.SGD","IE00BZ08YR35.GBP","LU0819121731.USD","02269","LU1242518857.USD","02096","01276","06990","SG9999002562.SGD","00013","02273","01951","03692","LU2097828631.EUR","09966","LU0737861772.HKD","01093","01952","06160","LU0181495838.USD","01177","03329","06996","02162","01530","09926","HK0000320264.USD","LU0502904849.HKD","LU1226287875.USD","LU0348827113.USD","BK1191","BK1576","LU0320764599.SGD","03759","02268","06078","IE00B0JY6N72.USD","LU1880383366.USD","LU2399975544.HKD","02596","LU0051755006.USD","LU1960683339.HKD","06821","LU1688375341.USD","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642744524","title":"智通港股早知道 | 美国5月CPI同比上涨4.2% 工信部：加强高端光电芯片和器件研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642744524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642744524?lang=zh_cn&edition=full","pubTime":"2026-06-11 07:42","pubTimestamp":1781134977,"startTime":"0","endTime":"0","summary":"热门中概股多数下跌，纳斯达克中国金龙指数跌0.28%。美国5月CPI同比上涨4.2%美国劳工部10日发布的数据显示，受能源价格上涨推动，美国5月消费者价格指数同比上涨4.2%，创2023年5月以来新高。其他在产锂精矿工厂的运营不受此次事件影响。报道称，蚂蚁、General Atlantic和Silver Lake代表均不予置评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BGHQF631.EUR","LU1119994496.HKD","LU1951186391.HKD","IE0034235188.USD","LU0943347566.SGD","LU0276348264.USD","LU0787776722.HKD","SG9999011175.SGD","IE00BLSP4239.USD","LU0289739343.SGD","IE00BN29S564.USD","LU2095319765.USD","LU2211814178.USD","LU0889566641.SGD","LU2720916845.USD","BK4581","BK1589","SG9999000418.SGD","LU0719512351.SGD","LU1037948541.HKD","LU1951198990.SGD","LU1400636657.SGD","LU2756315318.SGD","BK4527","LU0079474960.USD","IE00B4JS1V06.HKD","LU2764262908.HKD","QCML","SG9999015978.USD","IE0034235303.USD","LU1935042991.SGD","LU2347655073.USD","LU1852331112.SGD","LU1732799900.SGD","LU1064131342.USD","LU0511384066.AUD","LU0965509010.AUD","LU2087625088.SGD","AVGO","BK4533","LU0642271901.SGD","01763","LU0215105999.USD","HK0000914660.USD","LU0345768153.USD","LU1152091754.HKD","LU2023250504.SGD","BK1191","LU0345769631.USD","IE00BK4W5L77.USD","BK0196","LU1037948897.HKD","AVGG","LU0143551892.USD","LU1868836591.USD","LU2433249047.HKD","LU2954938101.SGD","IE00BGHQDM52.EUR","01277","SG9999003800.SGD","LU1202635105.USD","LU2430703251.USD","LU2028103732.USD","LU2065171402.SGD","LU2271345857.HKD","LU0964807845.USD","LU0006306889.USD","LU2272731600.USD","IE00BJTD4N35.SGD","LU0106261372.USD","LU2168564222.USD","BK0155","LU0225283273.USD","LU2242649171.HKD","LU2430703178.SGD","LU0354030438.USD","GB00BDT5M118.USD","LU0889565833.HKD","LU0788109477.HKD","LU1989764748.USD","IE00B19Z3581.USD","LU0353189763.USD","IE00BWXC8680.SGD","LU1226288170.HKD","LU1804176565.USD","BK1546","LU0501845795.SGD","IE00BYV24P56.USD","LU0061474960.USD","LU1813983027.USD","IE00B7KXQ091.USD","IE00BVYPNV92.GBP","LU0174119429.USD","LU1868837300.USD","IE00BZ08YR35.GBP","LU0965509101.SGD","BK1515","LU0320765646.SGD","IE00B3S45H60.SGD","LU1974910355.USD","LU2054465674.USD","IE00B775SV38.USD","IE00BKPKM429.USD","BK1155","AVGU","BK0077","LU1069344957.HKD","LU2360106780.USD","IE00B3PB1722.GBP","LU2931357623.SGD","LU2543165471.USD","LU2063271972.USD","LU1923623000.USD","LU2023250843.SGD","LU1670627923.USD","CHSTY","LU0067412154.USD","LU2048586759.USD","LU2213496289.HKD","HK0000165453.HKD","LU2237443382.USD","LU2417539215.USD","LU0238689110.USD","IE00BMPRXQ63.HKD","LU2250418816.HKD","LU2265009873.SGD","IE00B5MMRT66.SGD","LU2106854487.HKD","LU0127658192.USD","LU1992135472.HKD","LU2756315664.SGD","LU0203345920.USD","IE00BN8TJ469.HKD","BK4532","IE00BJJMRX11.SGD","LU0210536198.USD","LU0348723411.USD","LU1400636491.USD","LU0203347892.USD","BK0197","BK4561","IE00B19Z3B42.SGD","LU2456880835.USD","LU1003077747.HKD","LU0053666078.USD","LU0211327993.USD","LU0820561909.HKD","HK0000914686.HKD","LU0861579265.USD","LU1670711123.USD","LU1992135399.USD","LU2279689827.SGD","LU1718418525.SGD","LU2750360997.AUD","LU1642822529.SGD","LU2463028550.USD","LU0868494708.USD","LU2125909247.SGD","IE0009356076.USD","LU1935043023.USD","LU0314109678.HKD","BK1518","LU2473716301.USD","IE00B7SZLL34.SGD","LU2168564149.EUR","LU2237957811.SGD","BK1521","LU2360032135.SGD","LU2065171311.SGD","LU1989764664.SGD","LU1934455194.USD","LU2237438978.USD","LU2168564065.EUR","IE00BSNM7G36.USD","LU0158827948.USD","LU1145028129.USD","LU0210528500.USD","BK1574","00658","HK0000532082.HKD","IE00BZ08YT58.USD","LU0080751232.USD","LU2461242641.AUD","BK1178","LU2286300806.USD","LU1366333091.USD","LU1035775433.USD","LU1323610961.USD","LU1868836914.USD","LU0345770308.USD","IE00BKDWB100.SGD","LU1720051017.SGD","LU2471134952.CNY","LU0949170772.SGD","IE0004445015.USD","LU0738911758.USD","LU1226287529.USD","LU0444973449.USD","LU1674673691.USD","LU0256863902.USD","LU1917777945.USD","LU1645745479.HKD","LU2272731782.SGD","LU2168563687.JPY","IE00BLSP4452.SGD","LU1778281490.HKD","IE00BVYPNQ40.USD","BK4566","SG9999015945.SGD","LU1670756490.USD","LU2896262040.SGD","LU1066051225.USD","LU1267930730.SGD","LU0210533765.USD","LU0109392836.USD","AVL","LU0957808578.USD","LU0234570918.USD","LU2458330243.SGD","LU2505996681.GBP","LU1046421795.USD","LU0070217475.USD","BK4612","LU1629891620.HKD","09696","LU0823434740.USD","IE0004445239.USD","LU0326950275.SGD","LU2092937221.SGD","LU0868494617.USD","LU0234572021.USD","LU1670711040.USD","SG9999002232.USD","LU0203202063.USD","LU1226287792.SGD","LU1815333072.USD","LU2458330169.SGD","LU2637965513.SGD","LU2089985449.USD","LU0444971666.USD","IE0001KFT4U8.USD","LU2322448791.USD","IE0005OL40V9.USD","LU2236285917.USD","LU0057025933.USD","LU2242650005.HKD","LU1814569148.SGD","LU0170899867.USD","LU0965509283.SGD","LU2210149790.SGD","LU0251132253.USD","IE00BJJMRY28.SGD","IE0008368742.USD","LU0274383776.USD","LU1988902786.USD","LU0795875086.SGD","LU1815336760.USD","IE00B1BXHZ80.USD","LU2210150020.SGD","LU1989772923.USD","LU0823434583.USD","LU0061474705.USD","LU2420271590.USD","IE00BMPRXR70.SGD","LU1008478684.HKD","SGXZ81514606.USD","IE00BFSS8Q28.SGD","LU0640476718.USD","LU2602419157.SGD","LU1127390331.HKD","LU0726765562.USD","LU2746668461.USD","BK4554","LU2860962120.EUR","LU0466842654.USD","LU0795875169.SGD","LU2023250330.USD","LU0476273544.USD","LU0198837287.USD","LU0689626769.HKD","LU0256863811.USD","LU1244550221.USD","LU0672654240.SGD","LU2471134523.USD","IE00BMCWC346.EUR","LU2065169927.USD","IE00B031HY20.USD","LU2237443465.HKD","LU1261432733.SGD","AVS","MU","LU0323591593.USD","LU1914381329.SGD","LU0109391861.USD","IE0008369823.USD","BK4553","BK4604","SG9999015952.SGD","LU1162221912.USD","LU2211815571.USD","LU2471134796.USD","BK4585","BK4515","LU2361044949.HKD","LU2505996509.AUD","QCMU","LU1153585028.USD","LU0942090050.USD","LU2237443895.HKD","SG9999004303.SGD","LU2108987350.USD","LU2041044095.USD","LU0792757196.USD","LU1551013342.USD","LU0661504455.SGD","IE00BK4W5M84.HKD","SG9999002224.SGD","IE00B543WZ88.USD","LU0310799852.SGD","LU2471134879.HKD","LU1989772840.SGD","BK4579","LU2089284900.SGD","LU2462591277.SGD","LU2355687059.USD","IE00BVYPNW00.USD","BK1526","LU2125154935.USD","LU0320765059.SGD","LU1551013425.SGD","LU1226288253.USD","LU2357305700.SGD","LU0912757837.SGD","LU2023251221.USD","IE00BQXX3C00.GBP","LU1066051498.USD","SG9999001424.SGD","LU1366192091.USD","LU2111349929.HKD","LU2298321311.HKD","LU2083900584.USD","BK1161","LU0553294199.USD","LU2039709279.SGD","LU0683600562.USD","BK1586","LU1923622614.USD","LU2360108059.USD","LU1720051108.HKD","LU1280957306.USD","LU1623119135.USD","LU0354030511.USD","LU0784385840.USD","LU2592432038.USD","BK4598","LU1548497426.USD","LU2322448957.HKD","LU1670628061.USD","LU1868836757.USD","LU0417517546.SGD","IE00B19Z9Z06.USD","BK4588","LU1670710661.SGD","LU2764263203.CNY","LU0211328371.USD","LU2125909593.SGD","SGXZ23171101.USD","LU1935042488.USD","LU1244550577.SGD","IE00BZ1G4Q59.USD","IE00B19Z9P08.USD","LU0011850046.USD","LU0048584097.USD","LU2361045086.USD","LU2403377893.USD","LU0072462426.USD","LU1674673428.USD","LU2764263039.SGD","LU1152091168.USD","LU1084165304.USD","MUD","LU0315179316.USD","LU0708995401.HKD","LU0784384876.USD","LU0472753341.HKD","LU2487616109.SGD","BK1205","LU1267930813.SGD","00354","BK4573","IE00BFSS7M15.SGD","LU0124676726.USD","AVGX","LU1066053197.SGD","LU1803068623.USD","SG9999004220.SGD","LU2347655156.SGD","LU0345769128.USD","LU1868837136.USD","LU0082616367.USD","LU2065170008.USD","SG9999015986.USD","IE00B5949003.HKD","LU2237957902.USD","LU0820561818.USD","QCMD","LU1066051811.HKD","LU0314104364.USD","LU2237443622.USD","LU1242518931.SGD","LU1244550494.USD","LU2244417387.USD","BK4512","LU2750360641.GBP","01093","LU0158827781.USD","BK1222","LU1823568750.SGD","MUU","LU1316542783.SGD","BK0182","LU2237443549.SGD","SG9999001440.SGD","IE00BDGV0183.EUR","LU1807302812.USD","LU1934455277.USD","IE00B1XK9C88.USD","LU2999663052.SGD","BK0183","00031","LU0140636845.USD","LU2746668974.SGD","LU0820562030.AUD","LU0154236417.USD","LU0689472784.USD","LU0061475181.USD","LU1301847155.USD","LU2247934214.USD","LU0545039389.USD","LU0133085943.USD","BK4605","LU0786609619.USD","IE00B775H168.HKD","LU0724617625.USD","LU2133065610.SGD","IE00BZ08YS42.EUR","LU1732800096.USD","LU0187121727.USD","LU2357627491.SGD","LU0784385170.HKD","LU2168564495.EUR","LU0081259029.USD","BK4575","IE00BJLML261.HKD","LU2462157665.USD","LU1496350502.SGD","LU1328277881.USD","AVGW","LU2125154778.USD","BK4141","LU0097036916.USD","LU0985320562.USD","LU0316494557.USD","LU0784383803.USD","LU0345770993.USD","LU1691799644.USD","LU1670710588.SGD","BK0028","IE00BMPRXN33.USD","09966","LU0949170426.SGD","LU0957791311.USD","LU0345768740.USD","LU1993786604.SGD","IE00BBT3K403.USD","002466","LU0069063385.USD","LU2237443978.SGD","IE00BJTD4V19.USD","LU0072913022.USD","LU1951200564.SGD","LU2089283258.USD","LU2361044865.SGD","LU1267930490.SGD","LU1803068979.SGD","IE00BQXX3F31.USD","LU0203201768.USD","LU0353189680.USD","IE00BVYPNP33.GBP","LU2462591350.SGD","IE00B42XCP33.USD","LU1400636574.HKD","LU0096362180.USD","LU0157215616.USD","IE0002270589.USD","IE00B894F039.SGD","LU0880133367.SGD","MULL","LU1934455863.HKD","LU0965508806.USD","LU0308772762.SGD","SGXZ99366536.SGD","LU0289961442.SGD","BK4551","LU0979878070.USD","BK4543","LU1935042215.USD","SGXZ51526630.SGD","LU1712237335.SGD","LU0266013472.USD","LU1960683339.HKD","LU1935043536.SGD","LU2272731865.HKD","BK4534","BK0233","LU2264538146.SGD","IE00BZ9MQY76.HKD","LU0096364046.USD","LU0056508442.USD","BK1179","QCOM","LU2430703095.HKD","LU1242518857.USD","IE00BQXX3D17.EUR","LU1232071149.USD","LU1226287875.USD","IE00BKVL7J92.USD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642842817","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)一线治疗HER2阳性晚期乳腺癌的III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642842817","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642842817?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:05","pubTimestamp":1781089518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛用于人类表皮生长因子受体2阳性晚期乳腺癌一线治疗的III期临床研究，经独立数据监察委员会评估，成功达到预先设定的主要终点无进展生存期，结果具有显著的统计学和临床双重意义。曲妥珠单抗联合帕妥珠单抗和多西他赛目前仍是国内外HER2+晚期乳腺癌一线治疗的首选方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK1161","09966","BK1574","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164726076","title":"康宁杰瑞制药-B：安博利单抗（KN026）一线治疗HER2+晚期乳腺癌III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1164726076","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164726076?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:01","pubTimestamp":1781089276,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B宣布，其核心候选药物安博利单抗（研发代号：KN026）在一线治疗HER2阳性晚期乳腺癌的III期临床研究中，成功达到了预设的主要研究终点。这项关键性研究的积极结果，标志着该药物在攻克这一重大疾病领域迈出了坚实的一步，为其后续的上市申请奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641193035","title":"康宁杰瑞制药-B：执行董事及管理层增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641193035","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641193035?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:22","pubTimestamp":1780618920,"startTime":"0","endTime":"0","summary":" 康宁杰瑞制药-B发布公告，公司董事会已获徐霆博士告知，彼于2026年6月4日以自有资金在公开市场购入合共55.4万股公司普通股。徐霆博士及有关管理层成员购入的所有股份总代价为498.5万港元，相当于每股股份约7.375港元的平均购买价。紧随本次股份增持后，徐霆博士直接及间接持有合共3.14亿股股份，占公司已发行股份总数的约32.4%。在遵守适用法律及法规的前提下，徐霆博士及有关管理层成员并不排除其可能适时进一步增持公司股份的可能性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-05/doc-iniaicuz1949381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09966","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120337363","title":"康宁杰瑞制药-B6月4日回购15.60万股股份，总额约110.85万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120337363","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120337363?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:06","pubTimestamp":1780618003,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年6月5日发布公告，披露公司在2026年6月4日进行股份回购，回购数量为156,000股，占回购前已发行股份总数约0.0161%。本次回购价格区间介乎每股7.04港元至7.15港元，合计付出约110.85万港元。公告显示，公司购回授权于2025年6月12日获股东大会通过，可购回股份总数为96,218,980股；截至目前，已在交易所等渠道累计购回2,923,000股，占授权通过当日公司已发行股本约0.3038%。公司同时确认，本次回购严格遵守香港联交所之上市规则及相关法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B6月4日回购15.60万股股份，总额约110.85万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641935651","title":"康宁杰瑞制药-B(09966)6月4日斥资110.85万港元回购15.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641935651","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641935651?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:04","pubTimestamp":1780617860,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年6月4日斥资110.85万港元回购15.6万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149865177","title":"康宁杰瑞制药-B：股份回购总代价达499万港元，每股作价7.375港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149865177","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149865177?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:02","pubTimestamp":1780617734,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（Alphamab Oncology）宣布，其股份回购计划已累计支付总代价达499万港元，每股平均作价为7.375港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112268190","title":"康宁杰瑞制药-B2026年5月股份变动月报：新增发行88,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112268190","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112268190?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:52","pubTimestamp":1780570348,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年6月4日披露截至2026年5月31日的证券变动月报表。月报显示，公司本月法定/注册股本无变化，仍为25,100,000,000股普通股，面值USD 0.000002，法定/注册股本总额维持USD 50,200。库存股份数量维持在5,719,000股不变，已发行股份总数由974,293,697股增至974,381,697股。根据首次公开发售后购股权计划，本月因行使股份期权新增发行普通股88,000股，行使期权所得资金总额为HKD 421,476；另有48,000股购股权在本月失效。首次公开发售前的两项购股权计划均无变动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640993958","title":"康宁杰瑞制药-B(09966)：JSKN016的最新研究成果于2026年ASCO年会呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640993958","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640993958?lang=zh_cn&edition=full","pubTime":"2026-06-02 08:27","pubTimestamp":1780360021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，JSKN016治疗HER2-局部晚期或转移性BC的I期临床研究的最新研究成果，已于2026年5月29日至6月2日举行的2026年 ASCO年会上，于壁报展示期间公布。 该研究结果为JSKN016在一线治疗、围手术期联合化疗、免疫治疗及其他靶向治疗的探索奠定了坚实基础。目前，JSKN016已开展单药和联合疗法治疗肺癌、BC 等多项II期临床研究，治疗TNBC的III期临床研究正在进行中，有望为患者带来更高效、安全的治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260602/32266957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981528","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗BC的III期临床研究结果于2026 ASCO年会以LBA口头报告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981528","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981528?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:18","pubTimestamp":1780273113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛新辅助治疗HER2+ BC的III期临床研究的显著性结果已于2026 ASCO年会以LBA口头报告形式呈列。KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评估安尼妥单抗联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在早期及局部晚期HER2+ BC新辅助治疗中的疗效与安全性，主要终点为由BIRC评估的 tpCR。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4134","09966","BK4190","BC","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989809","title":"智通港股早知道 | 2026年国家医保目录调整工作方案发布 汇量科技(01860)Q1收入同比增长32.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640989809?lang=zh_cn&edition=full","pubTime":"2026-06-01 07:01","pubTimestamp":1780268492,"startTime":"0","endTime":"0","summary":"自2027年起，截止日期将固定为方案发布之日。成分股调整将于2026年6月12日(星期五)收市后实施，并于2026年6月15日(星期一)起生效。拟发行人民币股份事宜将取决于市场状况及必要的监管批准。目前，双方的合作进展顺利。要约价较股份于2024年8月30日在联交所所报收市价每股0.28港元折让约10.71%。根据捷利交易宝数据，截至5月29日16时，公开招股部分共录得券商孖展资金高达775.92亿港元，以公开发售集资额0.684亿港元计算，孖展超额认购高达1133.38倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","LU1951186391.HKD","LU0067412154.USD","BK4585","LU1226287875.USD","BK4588","LU1807302812.USD","IE0008368742.USD","BK1161","LU1152091754.HKD","LU1226287792.SGD","IE00BZ08YR35.GBP","IE00B031HY20.USD","IE0008369823.USD","LU1226287529.USD","BK1613","BK1574","BK1518","BK1137","BK1173","LU0072913022.USD","HK0000165453.HKD","01199","LU0314109678.HKD","BK1191","BK1515","IE00BZ08YS42.EUR","IE00B543WZ88.USD","SG9999004220.SGD","01093","LU1993786604.SGD","BK1521","LU0140636845.USD","LU0326950275.SGD","LU1813983027.USD","BK1586","LU1960683339.HKD","BK1535","LU0880133367.SGD","BK1590","LU1008478684.HKD","01860","LU1226288253.USD","IE00BZ08YT58.USD","LU1152091168.USD","02553","IE00B5MMRT66.SGD","VXUS","LU0315179316.USD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.0877},{"period":"1month","weight":0.178},{"period":"3month","weight":-0.2538},{"period":"6month","weight":-0.1207},{"period":"1year","weight":-0.1388},{"period":"ytd","weight":-0.1898}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.1164},{"period":"3month","weight":-0.0307},{"period":"6month","weight":-0.095},{"period":"1year","weight":-0.0098},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的ADCs、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的候选药物包括KN046（PD-L1/CTLA-4双特异性抗体）, KN026（抗HER2双特异性抗体）, KN035（皮下注射PD-L1）, JSKN003（HER2双表位ADC）等，用于1L sq NSCLC、乳腺癌 2+HER L1、晚期实体瘤、HER2表达实体瘤等适应症。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.117313},{"month":2,"riseRate":0.571429,"avgChangeRate":0.192959},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.039472},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098183},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.031094},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.059361},{"month":7,"riseRate":0.428571,"avgChangeRate":0.071228},{"month":8,"riseRate":0.333333,"avgChangeRate":0.022561},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}